SAHMRI Registry Centre

Visit the ANZASM website

Click here

Learn more about ASPIRE

Click here

Visit the ANZELA-QI website

Click here

Visit the BQA website

Click here

Visit the ACGR website

Click here

Visit the SABDR website

Click here

Visit the SACPR website

Click here

View the SA-PCCOC website

Click here

Visit the DIR website

Click here

View the ANZRAG website

Click here

Visit the ANZOD website

Visit the ANZLKD website

Click here

Visit the ANZETD website

Click here

Transcatheter Aortic Valve Implantation is an interventional procedure used for the treatment of aortic stenosis. Based at SAHMRI, the Transcatheter Aortic Valve Implantation Registry (TAVI-R) was established in 2018 as a clinical quality registry supported by the Australasian Cardiac Outcomes Registry (ACOR) Ltd. ACOR is an initiative of the Cardiac Society of Australia and New Zealand (CSANZ), which recognises the critical value of a national clinical cardiovascular quality registry incorporating quality, safety and appropriateness outcomes of patients undergoing aortic valve replacements via a transcatheter approach. A defined dataset is collected including patient characteristics, procedural techniques, device information and patient outcomes.

SAHMRI and ACOR work closely together to maintain and manage the registry of Transcatheter Aortic Valve Implantation procedures throughout Australia. With the support of TAVI performing hospitals, clinicians and device companies, data collected not only enables ongoing monitoring of the safety of the procedure and the devices used, but also promotes research opportunities to improve patient care.

All hospitals undertaking TAVI procedures are eligible to contribute data to the Registry. In order for a surgeon to be credentialed in Australia to perform TAVI procedures, please refer to the guidelines, ‘Position Statement for the Operator and Institutional Requirements for a Transcatheter Aortic Valve Implantation (TAVI) Program’ which are produced by CSANZ.

The Transcatheter Aortic Valve Implantation (TAVI) Registry aims to:

• Improve patient care and outcomes
• Educate clinicians and healthcare providers
• Identify areas of excellence and opportunities for improvement
• Ensure sites and clinicians meet the accreditation requirements to undertake TAVI procedures
• Provide an accurate and transparent assessment of the safety of the TAVI procedure and devices

For more information head to the TAVI website

Click here

The Australasian Registry of Electrocardiograms of National Athletes (ARENA) will collect and centralise cardiac screening data from across sports in Australia and New Zealand to facilitate current and future research. It is led by researchers at the University of Sydney, in collaboration with other national and international experts, and based at the SAHMRI Registry Centre. ARENA will be launched in 2023, initially in Australia with New Zealand to follow as funding allows.

Sudden cardiac death (SCD) in athletes is a rare but tragic event. Cardiac screening of elite athletes for conditions associated with SCD is now widely recommended by leading bodies such as the Australasian College of Sport and Exercise Physicians (ACSEP). Screening generally includes a personal and family history and a physical examination, together with a resting 12-lead electrocardiogram (ECG).

However, while many Australian and New Zealand sports are screening athletes, data are not structured to be shared, meaning few comparisons exist across different sports. In addition, diverse ethnic groups and female athletes are under-represented in research that informs current guidelines. 

ARENA is a registry that will bring together athlete screening data and ECGs collected in Australasia. All elite sports conducting cardiac screening of athletes (including ECG) will be eligible to provide data.

ARENA is working closely with participating sporting organisations, which will be able to use this registry to improve the quality of their cardiac screening programs and provide better cardiac care for young athletes.

ARENA is funded by an Australian Government National Health and Medical Research Council (NHMRC) Investigator Grant. ARENA is also endorsed by the Australasian College of Sport & Exercise Physicians (ACSEP).

ARENA aims to provide long-term national data to improve our understanding of:

• the role of various ethnicities (e.g. Indigenous Australians, Polynesian), age and sex in terms of accurate athlete ECG interpretation;
• the bounds of normal cardiac adaptations to exercise across athletes from different Australasian sports to provide relevant benchmarks for normal athlete ECG features and accurate interpretation; and outcomes of screened athletes.

The Australia and New Zealand Vasculitis Quality and Disease Registry (ANZVASC-QDR) will commence in 2023. The registry has been designed and is being implemented to include all forms of vasculitis.

The initial focus will be on anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). AAV comprises diseases associated with the presence of ANCA that cause inflammation of small blood vessels. The AAV are categorised as granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and as eosinophilic granulomatosis with polyangiitis (EGPA). The ANZVASC-QDR will also focus on some forms of large vessel vasculitis (including giant cell arteritis).

Initially, five sites will be involved including two in South Australia, with more sites added after the initial phase. Multisite ethics and National Mutual Acceptance approval for the project has been obtained for Australia, with a separate approval for New Zealand. ANZVASC, via the ANZVASC Registry Committee and the Board, directs the registry with Monash University being the Data Custodian organisation.

The ANZVASC-QDR data set will include relevant demographic and social data, clinical data and investigations at diagnosis and enrolment, as well as routine clinical data from each annual review, as the results of annual routine investigations and other investigations that are obtained as part of routine care, as well as Patient Reported Outcomes (PRO) and Quality of Life (QOL) data. In some instances, data from other clinical reviews will be recorded.

The registry aims to:

• Provide Clinical Quality Data to participating units to improve care and outcomes for people with vasculitis
• Improve understanding of the quality of life of people with vasculitis and factors affecting these conditions
• Establish a resource to enable and support research on vasculitis in Australia and New Zealand
• Serve as a platform for registry linked clinical trials and surveillance of new therapies and practices.
• Improve training of those in specialties involved in the care of people with vasculitis.